bluebird bio (BLUE) News Today $2.86 -1.95 (-40.54%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$2.69▼$5.5350-Day Range$2.61▼$4.8352-Week Range$2.52▼$8.52Volume54.13 million shsAverage Volume4.24 million shsMarket Capitalization$312.71 millionP/E RatioN/ADividend YieldN/APrice Target$8.02 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLong-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levelsfinance.yahoo.com - December 10 at 1:05 PMLong-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling ...businesswire.com - December 9 at 3:24 PMLong-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Eventsfinance.yahoo.com - December 9 at 3:24 PMBluebird Bio’s Hold Rating Maintained Amid Launch Challenges and Market Competitionmarkets.businessinsider.com - December 9 at 10:24 AMbluebird bio (NASDAQ:BLUE) Upgraded by Morgan Stanley to "Equal Weight"americanbankingnews.com - December 9 at 5:05 AMbluebird bio (NASDAQ:BLUE) Upgraded to "Sell" by StockNews.comamericanbankingnews.com - December 9 at 4:27 AMEquities Analysts Offer Predictions for bluebird bio, Inc.'s FY2024 Earnings (NASDAQ:BLUE)americanbankingnews.com - December 9 at 2:28 AMBluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatmentmarketwatch.com - December 8 at 5:42 PMMidday movers: Lululemon, Paramount and moremsn.com - December 8 at 5:42 PMmarketbeat.com - December 8 at 1:55 PMmarketbeat.com - December 8 at 1:51 PMmarketbeat.com - December 8 at 1:41 PMmarketbeat.com - December 8 at 1:33 PMMorgan Stanley ups bluebird to equal weight ahead of FDA decisionmsn.com - December 8 at 12:42 PMFDA Approves World’s First Crispr Gene-Editing Drug for Sickle-Cell Diseasefinance.yahoo.com - December 8 at 12:42 PMmarketbeat.com - December 8 at 11:24 AMbluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's Howfinance.yahoo.com - December 1 at 12:58 PMbluebird bio Isn't Priced For Successseekingalpha.com - December 1 at 1:27 AMBuy bluebird bio's Lovo-Cel As It Transforms Sickle Cell Disease Treatmentseekingalpha.com - November 29 at 9:57 PMSkysona: The gene therapy that saved Darius’ life cannot help any more European childrenmsn.com - November 25 at 10:41 PMReassessing Bluebird Bio: Inflation Concerns Overblown, Underperformance Unjustified, and Growth Potential Undervaluedmarkets.businessinsider.com - November 20 at 7:56 PMHere's Why bluebird bio (NASDAQ:BLUE) Must Use Its Cash Wiselyfinance.yahoo.com - November 14 at 10:33 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Arbutus Biopharma (ABUS) and Bluebird Bio (BLUE)markets.businessinsider.com - November 10 at 8:15 PMAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Bluebird Bio (BLUE) and Marinus (MRNS)markets.businessinsider.com - November 10 at 8:15 PMHold Rating on Bluebird Bio: Assessing Financial Position, Future Prospects, and Product Launchesmarkets.businessinsider.com - November 8 at 8:01 PMbluebird bio, Inc. (NASDAQ:BLUE) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 8 at 8:01 PMAnalysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE) and Marinus (MRNS)markets.businessinsider.com - November 8 at 9:59 AMBluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesdaymsn.com - November 8 at 9:59 AMWhy Bluebird Bio Stock Soared 7% Higher on Tuesdayfinance.yahoo.com - November 7 at 7:10 PMbluebird (BLUE) Q3 Earnings Top; Zynteglo, Skysona Fuel Salesfinance.yahoo.com - November 7 at 2:09 PMHere's what Wall Street expects from bluebird bio's earnings reportmarkets.businessinsider.com - November 7 at 9:09 AMbluebird bio GAAP EPS of -$0.66 beats by $0.01, revenue of $12.39M misses by $1.02Mmsn.com - November 7 at 9:09 AMBluebird Bio Q3 Loss Narrows, Tops Estimates; Revenues Miss Estimatesmarkets.businessinsider.com - November 7 at 9:09 AMbluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progressfinance.yahoo.com - November 7 at 9:09 AMBluebird Bio Inc (BLUE) Reports Q3 2023 Financial Results: Strong Commercial Launch and ...finance.yahoo.com - November 7 at 9:09 AMbluebird bio Q3 2023 Earnings Previewmsn.com - November 6 at 10:49 PMHold Rating Retained for Bluebird Bio Amid Potential PRV Sale and Market Factorsmarkets.businessinsider.com - November 2 at 11:22 PMbluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Expositionfinance.yahoo.com - November 2 at 1:18 PMSensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officermarkets.businessinsider.com - November 1 at 10:11 AMPanel Says That Innovative Sickle Cell Cure Is Safe Enough for Patientsnytimes.com - October 31 at 6:20 PMBluebid bio to sell FDA voucher for $103M if sickle cell disease therapy approvedmsn.com - October 31 at 1:19 PMCure for sickle cell disease on the horizon? US drug regulator is reviewing 2 new gene therapiesmsn.com - October 31 at 1:19 PMBluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Releasefinance.yahoo.com - October 31 at 1:19 PMUPDATE 1-Bluebird bio to sell sickle cell FDA voucher for $103 mln if therapy approvedfinance.yahoo.com - October 30 at 9:21 AMBluebird bio to sell sickle cell gene therapy FDA voucher for $103 million if approvedreuters.com - October 30 at 9:21 AMbluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Millionfinance.yahoo.com - October 30 at 9:21 AMBluebird stock falls 10% ahead of FDA meeting for rival sickle cell therapymsn.com - October 27 at 6:13 PMBluebird Bio Stock Soars After Company Details Promising Cancer Treatmentthestreet.com - October 25 at 10:42 AMbluebird bio to Host Third Quarter 2023 Financial Results Conference Callfinance.yahoo.com - October 24 at 12:35 PMA Look At The Fair Value Of bluebird bio, Inc. (NASDAQ:BLUE)finance.yahoo.com - October 18 at 7:43 AM Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Media Mentions By Week BLUE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼0.500.52▲Average Medical News Sentiment BLUE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼224▲BLUE Articles Average Week Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alector News Today Allogene Therapeutics News Today ProKidney News Today Adaptimmune Therapeutics News Today Orchard Therapeutics News Today Cullinan Oncology News Today Fusion Pharmaceuticals News Today iTeos Therapeutics News Today Taysha Gene Therapies News Today MeiraGTx News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:BLUE) was last updated on 12/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.